Kepler Capital Markets Lowers GlaxoSmithKline plc (GSK) Price Target to GBX 1,340

GlaxoSmithKline plc (LON:GSK) had its price objective cut by Kepler Capital Markets from GBX 1,520 ($20.06) to GBX 1,340 ($17.68) in a report published on Wednesday morning. They currently have a reduce rating on the stock.

A number of other equities research analysts also recently commented on the stock. Citigroup Inc. downgraded shares of GlaxoSmithKline plc from a buy rating to a neutral rating and set a GBX 1,700 ($22.43) price objective on the stock. in a research report on Wednesday, July 5th. Jefferies Group LLC reissued a buy rating and issued a GBX 1,900 ($25.07) price objective on shares of GlaxoSmithKline plc in a research report on Thursday, July 13th. J P Morgan Chase & Co reissued a neutral rating and issued a GBX 1,750 ($23.09) price objective on shares of GlaxoSmithKline plc in a research report on Thursday, July 13th. Shore Capital reissued a hold rating on shares of GlaxoSmithKline plc in a research report on Friday, July 14th. Finally, Morgan Stanley reissued an equal weight rating and issued a GBX 1,700 ($22.43) price objective on shares of GlaxoSmithKline plc in a research report on Tuesday, July 18th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of GBX 1,619.75 ($21.37).

Shares of GlaxoSmithKline plc (LON:GSK) opened at GBX 1,361 ($17.96) on Wednesday.

GlaxoSmithKline plc (LON:GSK) last announced its earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) earnings per share for the quarter, topping the consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). GlaxoSmithKline plc had a negative net margin of 1.17% and a negative return on equity of 57.19%. The firm had revenue of GBX 784.30 billion for the quarter.

TRADEMARK VIOLATION WARNING: “Kepler Capital Markets Lowers GlaxoSmithKline plc (GSK) Price Target to GBX 1,340” was reported by BBNS and is the property of of BBNS. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://baseballnewssource.com/markets/kepler-capital-markets-lowers-glaxosmithkline-plc-gsk-price-target-to-gbx-1340/1747243.html.

The company also recently declared a dividend, which will be paid on Thursday, January 11th. Shareholders of record on Thursday, November 9th will be paid a dividend of GBX 19 ($0.25) per share. The ex-dividend date is Thursday, November 9th. This represents a dividend yield of 1.41%.

In related news, insider Urs Rohner bought 473 shares of the firm’s stock in a transaction that occurred on Wednesday, October 25th. The shares were acquired at an average cost of GBX 1,518 ($20.03) per share, with a total value of £7,180.14 ($9,474.98). Also, insider Simon Dingemans bought 1,076 shares of the firm’s stock in a transaction that occurred on Thursday, October 12th. The stock was bought at an average cost of GBX 1,527 ($20.15) per share, for a total transaction of £16,430.52 ($21,681.87). Insiders purchased 1,574 shares of company stock worth $2,398,888 over the last three months.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.